Ross E. Crabtree

731 total citations
24 papers, 554 citations indexed

About

Ross E. Crabtree is a scholar working on Endocrinology, Diabetes and Metabolism, Pharmacology and Molecular Biology. According to data from OpenAlex, Ross E. Crabtree has authored 24 papers receiving a total of 554 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Endocrinology, Diabetes and Metabolism, 6 papers in Pharmacology and 4 papers in Molecular Biology. Recurrent topics in Ross E. Crabtree's work include Pituitary Gland Disorders and Treatments (4 papers), Growth Hormone and Insulin-like Growth Factors (4 papers) and Cannabis and Cannabinoid Research (3 papers). Ross E. Crabtree is often cited by papers focused on Pituitary Gland Disorders and Treatments (4 papers), Growth Hormone and Insulin-like Growth Factors (4 papers) and Cannabis and Cannabinoid Research (3 papers). Ross E. Crabtree collaborates with scholars based in United States. Ross E. Crabtree's co-authors include Louis Lemberger, Howard Rowe, John T. Callaghan, Alan Rubin, Stanley M. Chernish, David T. Wong, Frank P. Bymaster, Jong S. Horng, Rocco L. Brunelle and Bernard D. Rosenak and has published in prestigious journals such as Science, The Journal of Clinical Endocrinology & Metabolism and Life Sciences.

In The Last Decade

Ross E. Crabtree

24 papers receiving 489 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ross E. Crabtree United States 13 260 119 102 72 71 24 554
Jürgen H. Hengstmann Germany 15 159 0.6× 65 0.5× 85 0.8× 110 1.5× 154 2.2× 35 743
R. K. Richards United States 13 167 0.6× 115 1.0× 36 0.4× 68 0.9× 46 0.6× 42 565
M Widman Sweden 14 520 2.0× 227 1.9× 62 0.6× 76 1.1× 64 0.9× 31 739
George D. Olsen United States 17 152 0.6× 104 0.9× 33 0.3× 137 1.9× 71 1.0× 41 824
Robert L. Roe United States 11 138 0.5× 71 0.6× 114 1.1× 67 0.9× 42 0.6× 19 592
M Rowland Canada 13 121 0.5× 131 1.1× 81 0.8× 81 1.1× 14 0.2× 23 606
David W. J. Clark New Zealand 17 163 0.6× 156 1.3× 77 0.8× 199 2.8× 132 1.9× 37 944
Niels‐Erik Larsen Denmark 20 245 0.9× 96 0.8× 125 1.2× 171 2.4× 50 0.7× 44 1.1k
Henrik Björk Sweden 7 233 0.9× 85 0.7× 30 0.3× 99 1.4× 61 0.9× 12 681
M. M. Reidenberg United States 12 70 0.3× 35 0.3× 51 0.5× 133 1.8× 48 0.7× 27 659

Countries citing papers authored by Ross E. Crabtree

Since Specialization
Citations

This map shows the geographic impact of Ross E. Crabtree's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ross E. Crabtree with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ross E. Crabtree more than expected).

Fields of papers citing papers by Ross E. Crabtree

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ross E. Crabtree. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ross E. Crabtree. The network helps show where Ross E. Crabtree may publish in the future.

Co-authorship network of co-authors of Ross E. Crabtree

This figure shows the co-authorship network connecting the top 25 collaborators of Ross E. Crabtree. A scholar is included among the top collaborators of Ross E. Crabtree based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ross E. Crabtree. Ross E. Crabtree is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Walker, Laura, et al.. (2016). 253 A Multifaceted Approach to Improved Timeliness of Analgesia for Long Bone Fractures and Patient Satisfaction With Pain Management. Annals of Emergency Medicine. 68(4). S98–S98. 1 indexed citations
2.
Foster, Richard S., et al.. (1990). Role of serum prolactin determination in evaluation of impotent patient. Urology. 36(6). 499–501. 17 indexed citations
3.
Callaghan, John T., R. F. Bergstrom, Alan Rubin, et al.. (1987). A Pharmacokinetic Profile of Nizatidine in Man. Scandinavian Journal of Gastroenterology. 22(sup136). 9–17. 40 indexed citations
4.
Wolen, Robert L., et al.. (1984). Tracer microspheres as compliance markers in clinical research. Controlled Clinical Trials. 5(4). 540–543. 6 indexed citations
5.
Callaghan, John T., Robert E. Cleary, Ross E. Crabtree, & Louis Lemberger. (1981). Clinical response of patients with galactorrhea to pergolide, a potent, long-acting dopaminergic ergot derivative. Life Sciences. 28(1). 95–102. 13 indexed citations
6.
Lemberger, Louis, Ross E. Crabtree, & John T. Callaghan. (1980). Pergolide, a potent long-acting dopamine-receptor agonist. Clinical Pharmacology & Therapeutics. 27(5). 642–651. 34 indexed citations
7.
Rubin, Alan, et al.. (1979). The disposition of l-3-[(dimethylamino)-(m-dioxan-5-yl)methyl]pyridine in man.. Drug Metabolism and Disposition. 7(3). 149–154. 5 indexed citations
8.
Chernish, Stanley M., Bernard D. Rosenak, Rocco L. Brunelle, & Ross E. Crabtree. (1979). Comparison of gastrointestinal effects of aspirin and fenoprofen. Arthritis & Rheumatism. 22(4). 376–383. 39 indexed citations
9.
Rubin, Alan, Louis Lemberger, Ross E. Crabtree, et al.. (1978). Physiologic disposition of lergotrile. Clinical Pharmacology & Therapeutics. 23(3). 272–280. 4 indexed citations
10.
Lemberger, Louis, Howard Rowe, Ross E. Crabtree, et al.. (1978). Fluoxetine, a selective serotonin uptake inhibitor. Clinical Pharmacology & Therapeutics. 23(4). 421–429. 88 indexed citations
11.
Cleary, Robert E., Ross E. Crabtree, & Louis Lemberger. (1975). The Effect of Lergotrile on Calactorrhea and Gonadotropin Secretion. The Journal of Clinical Endocrinology & Metabolism. 40(5). 830–833. 12 indexed citations
12.
Murphy, P. J., et al.. (1975). Metabolism of propionyl erythromycin lauryl sulfate. II. Fate of the lauryl sulfate moiety in the rat and man.. PubMed. 3(3). 164–70. 2 indexed citations
13.
Rubin, Alan, Stanley M. Chernish, Ross E. Crabtree, et al.. (1974). Section 2 A profile of the physiological disposition and gastro-intestinal effects of fenoprofen in man. Current Medical Research and Opinion. 2(9). 529–544. 14 indexed citations
14.
Lemberger, Louis, et al.. (1974). The Inhibitory Effect of an Ergoline Derivative (Lergotrile, Compound 83636) on Prolactin Secretion in Man. The Journal of Clinical Endocrinology & Metabolism. 39(3). 579–584. 23 indexed citations
15.
Crabtree, Ross E., et al.. (1973). Tracer microspheres as a fecal marker in balance studies. Clinical Pharmacology & Therapeutics. 14(6). 987–991. 5 indexed citations
16.
Lemberger, Louis, Ross E. Crabtree, & Howard Rowe. (1972). 11-Hydroxy-Δ 9 -tetrahydrocannabinol: Pharmacology, Disposition, and Metabolism of a Major Metabolite of Marihuana in Man. Science. 177(4043). 62–64. 103 indexed citations
17.
Baum, William E., et al.. (1964). Immunoassay for Extracted Insulin. Journal of Pharmaceutical Sciences. 53(7). 738–745. 3 indexed citations
18.
Nash, J. Frank & Ross E. Crabtree. (1961). Absorption of Tritiated d-Desoxyephedrine in Sustained-Release Dosage Forms. Journal of Pharmaceutical Sciences. 50(2). 134–137. 5 indexed citations
19.
Crabtree, Ross E., et al.. (1958). A Study of the Oxidative Metabolism of Acetylsalicylic, Salicylic, and Gentisic Acid in Fevered Animals**Bionucleonics Laboratories, School of Pharmacy, Purdue University, Lafayette, Ind.. Journal of the American Pharmaceutical Association (Scientific ed ). 47(8). 602–605. 4 indexed citations
20.
Crabtree, Ross E., et al.. (1956). A Study of the Carbon-14 Content of Blood After the Oral Administration of C14-Carboxyl Acetylsalicylic Acid to Nonfevered and Fevered Rats*. Journal of the American Pharmaceutical Association (Scientific ed ). 45(10). 667–669. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jürgen H. Hengstmann Breakdown of academic impact, for papers by R. K. Richards Breakdown of academic impact, for papers by M Widman Breakdown of academic impact, for papers by George D. Olsen Breakdown of academic impact, for papers by Robert L. Roe Breakdown of academic impact, for papers by M Rowland Breakdown of academic impact, for papers by David W. J. Clark Breakdown of academic impact, for papers by Niels‐Erik Larsen Breakdown of academic impact, for papers by Henrik Björk Breakdown of academic impact, for papers by M. M. Reidenberg
Rankless by CCL
2026